3 AI Healthcare Stocks Investors May Be Watching Including AstraZeneca

With oil prices swinging on Middle East tensions and central banks recalibrating their rate paths, investors are hunting for themes that are less tied to traditional economic cycles and more to long-term structural change. Transformative artificial intelligence in healthcare sits firmly in that camp, where AI is being used to sharpen diagnostics, customize treatments, and cut costs for overstretched health systems. This screener focuses on companies applying AI in ways that aim to improve accuracy and access to care. In this article, you will see three stocks from this Transformative AI Healthcare Stocks list.

IXICO (AIM:IXI)

Overview: IXICO is a London based medical imaging and data analytics company that supports biopharma clinical trials in neurological diseases by collecting, managing, and analysing complex brain imaging and related clinical data through its AI enabled IXICO platform. Its services are used across conditions such as Alzheimer’s, Huntington’s, Multiple Sclerosis, Parkinson’s and other rare neurological disorders.

Operations: IXICO currently generates around £7.3 million in revenue from its Medical Labs & Research activities.

Market Cap: £18.5 million

IXICO sits at the intersection of AI and neurology, using its IXI v10.0 neuroimaging platform and long standing expertise to help drug developers run more precise and efficient brain disease trials, from Alzheimer’s PET imaging to Parkinson’s MRI biomarker work with the Paris Brain Institute. Recent contract wins and guidance for higher revenues indicate that customers are engaging with its specialist offer. However, the company remains loss making, with declining forecast earnings and a history of shareholder dilution and share price volatility. For investors focused on AI healthcare, the balance between IXICO’s niche positioning in brain imaging, its collaborations, and the clear profitability and governance risks is a key consideration.

IXICO’s AI neurology niche and recent contract momentum could be masking a much sharper risk reward profile than the headline losses suggest, so it is worth scanning the 1 key reward and 4 important warning signs in the 1 key reward and 4 important warning signs (2 are major!)

AstraZeneca (LSE:AZN)

Overview: AstraZeneca is a global biopharmaceutical company based in Cambridge that develops, manufactures, and sells prescription medicines across cancer, cardiovascular and metabolic disease, respiratory and immunology, vaccines, and rare diseases, including well known therapies such as Tagrisso, Imfinzi, Enhertu, Farxiga and Soliris.

Operations: AstraZeneca generates about US$60.4b in revenue from its Pharmaceuticals segment.

Market Cap: £192.0b

AstraZeneca stands out in AI enabled healthcare because it combines a large, diversified drug portfolio with investment in data driven R&D, including AI partnerships with Tempus, Nucs AI and others to support clinical trials and oncology response prediction. Recent earnings, return on equity and margins have been strong, with margins improving to 17.2%. At the same time, debt levels, reliance on blockbuster drugs such as Tagrisso and Imfinzi, and growing price pressure from regulators and biosimilars contribute to the risk profile. Recent oncology approvals and licensing deals sit alongside trial setbacks, so the current valuation debate remains open.

AstraZeneca’s strong margins and AI partnerships may hint at a story that is only partly reflected in the share price, but the real tension between growth, concentration risks and pricing pressure sits inside the 4 key rewards and 2 important warning signs

EMV Capital (AIM:EMVC)

Overview: EMV Capital is a London based venture capital company that backs early and growth stage businesses in areas such as digital health, AI enabled diagnostics, therapeutics, semiconductors, robotics and other deep tech fields that aim to improve outcomes for people with chronic diseases. It invests mainly in Europe, the UK and the US and looks to hold meaningful control in its principal subsidiaries.

Operations: EMV Capital currently generates about £2.87 million in revenue from Diagnostic Kits / Equipment, with most of this coming from the United Kingdom and smaller contributions from Europe, the United States and the Rest of World.

Market Cap: £14.8 million

EMV Capital gives you exposure to a portfolio of early stage healthcare and AI technologies through a single listed stock, with a revenue base of around £2.87 million and forecast revenue growth of 13.2% a year that is ahead of the wider UK market. The company is still loss making, has less than one year of cash runway and its auditor has highlighted uncertainty about its ability to continue as a going concern, so funding risk is front and center. At the same time, the share price sits well below one estimate of fair value and losses have been narrowing, under an experienced management team and a recently refreshed chair. The real question is how that mix of potential value, early signs of financial improvement and clear balance sheet risk compares with other AI healthcare options.

EMV Capital’s shrinking losses, refreshed leadership and early stage AI healthcare portfolio hint at a story the share price may not fully reflect yet, but the real twist sits inside the 3 key rewards and 2 important warning signs

The three stocks in this article are just a starting point. The full Transformative Artificial intelligence (AI) Healthcare Stocks list on Simply Wall St has uncovered 2 more companies with equally compelling AI in healthcare narratives inside the Transformative Artificial intelligence (AI) Healthcare Stocks screener. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter most to you so you can focus on the highest conviction AI healthcare opportunities rather than sorting through every stock manually.

Take Control of Your Investment Journey

If AstraZeneca or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond AI Healthcare?

Fresh stock ideas often see momentum build before the crowd catches on, and that window can drop fast while it still matters. Review these curated lists and consider acting before that window closes.

• Target resilient compounding potential by reviewing a curated 7 resilient stocks with low risk scores that aims to prioritise stability and balance sheet strength while sentiment remains under the radar for now.
• Explore early breakout energy across infrastructure by scanning a hand picked 33 power grid technology and infrastructure stocks positioned around long term electrification and grid upgrade themes.
• Look for overlooked upside in cutting edge automation through a carefully filtered 33 robotics and automation stocks that focuses on businesses applying robotics where real world adoption still feels early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com